Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Docetaxel plus Prednisolone with or without Zoledronic acid and/or Strontium-89 in hormone-refractory prostate cancer with bone metastases
2004-002295-41Phase 2Completed
- Sponsor
- University of Birmingham
- Start
- Jul 2005
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of docetaxel, prednisolone, zoledronic acid and Strontium chloride in castration-resistant prostate cancer (CRPC) (4 arms), sponsored by University of Birmingham. Primary endpoint: Primary endpoint at 200 patients accrued. Started Jul 2005; status: completed.
02
Drugs
docetaxelprednisolonezoledronic acidStrontium chloride
03
Conditions
castration-resistant prostate cancer (CRPC)
Beyond the preview
Go deeper on 2004-002295-41.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-002295-41.